Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Breast Cancer Res Treat. 2009 May;115(2):359-63. doi: 10.1007/s10549-008-0128-9. Epub 2008 Jul 23.


Background: Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy.

Methods: The excised breast tissue and lymph nodes were examined for the presence of residual disease.

Results: Pathologic complete response was observed in nine patients (90%).

Conclusions: Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology
  • Cisplatin / therapeutic use*
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Mastectomy
  • Middle Aged
  • Mutation
  • Neoadjuvant Therapy / methods*
  • Ubiquitin-Protein Ligases / genetics*


  • Antineoplastic Agents
  • BRAP protein, human
  • Ubiquitin-Protein Ligases
  • Cisplatin